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Abstract
 Purpose of review—Denervation is a hallmark of age-related and other types of muscle 
wasting. This review focuses on recent insights and current viewpoints regarding the mechanisms 
and clinical relevance of maintaining the neuromuscular junction to counteract muscle wasting 
resulting from aging or neural disease/damage.
 Recent findings—Activity-dependent regulation of autophagy, the agrin-MuSK-Lrp4 
signaling axis, and sympathetic modulation are principal mechanisms involved in stabilizing the 
neuromuscular junction. These findings are derived from several animal models and were largely 
confirmed by human gene expression analysis as well as insights from rare neuromuscular 
diseases such as amyotrophic lateral sclerosis and congenital myasthenic syndromes. Based on 
these insights, agrin-derived fragments are currently being evaluated as biomarkers for age-related 
muscle wasting. Tuning of autophagy, of the agrin pathway, and of sympathetic input are being 
studied as clinical treatment of muscle wasting disorders.
 Summary—Basic research has revealed that maintenance of neuromuscular junctions and a 
few signaling pathways are important in the context of age-dependent and other forms of muscle 
wasting. These findings have recently started to enter clinical practice, but further research needs 
to substantiate and refine our knowledge.
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 Introduction
Sedentary lifestyle and aging make muscle wasting an increasing health burden. Being at the 
crossroad between nerve and muscle [1], neuromuscular junctions are entering center stage 
for basic concepts, diagnosis and therapy of muscle wasting [2]. Recent progress in the 
understanding of neuromuscular junction functions in muscle wasting and their application 
to clinical aspects are reviewed here.
 Muscle wasting, the atrogene concept, and neuromuscular junction
Several conditions including aging, disuse, heart failure, diabetes, cancer, and 
neuromuscular transmission disorders lead to profound muscle wasting and weakness. A 
common set of proteins are strongly up- or down-regulated under different conditions 
leading to muscle wasting (also called muscle atrophy) and were termed ‘atrogenes’ [3]. 
Two of these proteins, namely Atrogin-1 and MuRF1 are E3 ubiquitin ligases and have been 
characterized as the key regulators for the proteasomal degradation of muscle tissue muscle 
wasting conditions. The finding that the neuromuscular junction fragments and loses 
functionality upon aging-related muscle wasting (sarcopenia) and other atrophic conditions 
and that these phenomena are partially reversible by metabolic maneuvers [4–8] have 
spurred interest in understanding the molecular links between muscle wasting and related 
neuromuscular junction phenotypes. Notably, while MuRF1 was generally considered to 
orchestrate sarcomeric protein degradation upon muscle wasting, it was recently found to be 
clearly enriched at the neuromuscular junction and to be involved in muscle wasting-induced 
autophagic degradation of a major neuromuscular junction component, i.e. nicotinic 
acetylcholine receptor (AChR) [9,10]. These studies linked the atrogene concept to 
neuromuscular junction maintenance and autophagy. Increased turnover of AChR, 
fragmentation of neuromuscular junctions, and precocious synaptic dysfunction including 
partial denervation were observed in mice with skeletal muscle-specific loss of Atg7, a 
principal component of the autophagy machinery [11]. This further supported a major role 
of autophagy for neuromuscular junction homeostasis. Accordingly, autophagy was found to 
be dysregulated in skeletal muscle of aging dogs [12] and humans [11]. It has been 
determined that caloric restriction and physical exercise are beneficial for rescuing 
neuromuscular junction fragmentation [2,13,8] and innervation status [2,14], and at the same 
time reduce impairment of autophagy [11] as well as sarcopenia onset or progression [15–
18]. This suggests autophagy modulation to be a potential therapeutic target in 
neuromuscular transmission disorders (Fig. 1).
 Agrin signaling – diagnostic and therapeutic toolbox for muscle wasting
While autophagy and other vesicular trafficking processes are key to the delivery, 
distribution, and degradation of neuromuscular junction components, the agrin-MuSK-Lrp4 
signaling axis mediates crosstalk between nerve and muscle [2] (Fig. 1). Indeed, neuronal 
agrin is released by the motor neuron into the synaptic cleft where it binds to the Lrp4 co-
receptor to activate the receptor tyrosine kinase MuSK. This leads to stabilization and 
clustering of AChR via Dok-7 and further mechanisms that involve also the 43 kDa-protein 
rapsyn. The agrin-MuSK-Lrp4 signaling pathway is of principal importance for the 
establishment and maintenance of neuromuscular junctions. Mutants in any of its 
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components are either not viable or develop severe neuromuscular transmission disorders 
termed congenital myasthenic syndromes (CMS) [2,19]. Also, neuromuscular junction 
remodeling that entails reorganization of AChR patches for maintaining a tight pre-to-
postsynaptic matching appears to require local cleavage of agrin. This is executed by the 
protease neurotrypsin and leaves a C-terminal agrin fragment (CAF, Fig. 1), which becomes 
soluble and circulates in the blood. Given massive neuromuscular junction remodeling in the 
course of some forms of muscle wasting and particularly during sarcopenia, the use of 
circulating CAF levels as a diagnostic tool of neuromuscular junction disintegration has 
become an attractive concept [20]. Indeed, recent clinical investigations supported the 
efficacy of CAF as a biomarker for sarcopenia primarily in men [21–23]. However, sample 
sizes in these studies are still small asking for larger trials.
Apart from the diagnostic relevance of CAF, a neurotrypsin-resistant and soluble N-terminal 
fragment of agrin (Fig. 1) was tested with respect to its therapeutic efficacy [24]. 
Subcutaneous injection of the compound into neurotrypsinoverexpressing mice largely 
rescued their sarcopenic phenotype, which includes severe precocious muscle wasting, 
weakness, and neuromuscular junction degeneration. Another study investigated the 
therapeutic efficacy of modulating Dok-7 abundance and revealed that adeno-associated 
virus-mediated gene therapy to overexpress Dok-7 was able to significantly reduce the 
symptoms of two different CMS models, including a prolongation of lifespan in an Emery-
Dreyfus CMS model and a complete rescue in Dok-7 knockout mice [25]. Although the 
therapeutic activity of both the N-terminal agrin fragment as well as the Dok-7 have been 
explored only in rodents so far, these studies suggest that neuromuscular junction-related 
muscle wasting might in the future be amenable for pharmacological intervention.
 Lrp4 and Slit2 – bidirectional communication at the nerve-muscle interface
As mentioned before, Lrp4 is a major mediator of postsynaptic stability at the 
neuromuscular junction [2] and its persistent activity is necessary to maintain synaptic 
integrity and function throughout adulthood as shown by inducible Lrp4 knockout mice [26]. 
While Lrp4 is now an established causative gene for some forms of CMS [27,28] it has 
recently also been implicated in the pathogenesis of a motor neuron disease, namely 
amyotrophic lateral sclerosis (ALS). Indeed, Lrp4 autoantibodies were found in a high 
proportion of ALS patients, while they were absent in other neurological disorders [29]. 
Some studies now consider ALS, which is characterized by late onset and fast progression, 
as a disease that originates at the neuromuscular junction followed by progressive ‘dying-
back’ of the rest of the neuron. Indeed, alterations of synaptic function [30], of the 
presynaptic terminal [31], and of terminal Schwann cells [32], which shield the 
neuromuscular junction, were found to precede symptom onset in mouse models of ALS and 
Charcot-Marie-Tooth disease. As recently reviewed, Lrp4 may act as a retrograde signal 
orchestrating presynaptic organization at the neuromuscular junction [2], thus potentially 
explaining these phenomena. However, given that Lrp4 is present in cis and in trans it 
remains open, if the initial neuromuscular junction damage occurred on the pre- or 
postsynaptic side. Evidence for a muscle-dependent retrograde signaling that determines 
neuromuscular junction presynaptic integrity comes from a recent report on the function of 
the releasable axonal guidance factor Slit2 [33]. Slit2 expression was reduced in mice 
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lacking muscle β-catenin, an effector of wnt signaling. Overexpression of Slit2 in these mice 
rescued all their phenotypes including impairment of terminal differentiation of the 
neuromuscular junction presynapse, axonal pathfinding, and synapse function [33]. A recent 
bioinformatics screen of aging-related alterations of gene expression in humans identified 
Slit2 to be significantly associated with physical capacity across 116 samples [34]. 
Furthermore, these data highlight a well established [2] but complex role [35,36] of wnt 
signaling in neuromuscular junction formation and maintenance as well as after traumatic 
injury [37]. The earlier mentioned screen of aging related alterations of gene expression in 
humans [34] also identified Amotl2. Together with other proteins, Amotl2 is a component of 
so-called podosomes which play a role in neuromuscular junction remodeling [38].
 Enigmatic treatment of CMS
CMS are rare hereditary neuromuscular transmission disorders that are caused by mutations 
in several principal components of the neuromuscular junction, including AChR, MuSK, 
Lrp4, Dok-7 and others [28]. Generally, neuromuscular junctions of CMS muscles are 
severely affected in terms of morphology and function, leading to muscle wasting and 
weakness. In clinical practice, many CMS patients have been found to respond well to 
treatment with β-adrenergic agonists, such as albuterol, salbutamol, or ephedrine 
[19,27,28,39] (Fig. 1). Fittingly, neuromuscular junctions have been recently identified as 
target of direct sympathetic innervention and this appears to be crucial for the homeostasis 
of neuromuscular junctions, for example by modulating AChR expression [40]. The 
mechanisms underlying the therapeutic efficacy of β-adrenergic agonists are likely 
pleiotropic in nature and might involve enhancement of gene expression [40], protein 
metabolism, inhibition of proteolysis, improvement of mitochondrial function, effects on the 
release of trophic factors and the modulation of immune cells [41].
 Conclusion
Several forms of muscle wasting, including sarcopenia, have an important denervation 
component. Although muscle wasting can be observed also in the absence of neuromuscular 
junction derangements [42], strong links between neuromuscular junction impairment and 
repair of muscle wasting in particular upon aging and neural damage have been observed. 
Accordingly, measures to maintain and enforce neuromuscular junctions are increasingly 
becoming a focus in clinical research.
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Key points
• Degeneration of neuromuscular junction is important in the context of 
some types of muscle wasting, particularly those resulting from aging 
or neural damage/disease.
• Degeneration of neuromuscular junctions is modulated by autophagy, 
the agrin-MuSK-Lrp4 and Wnt signaling axis, and sympathetic input.
• C-terminal fragment of agrin is being evaluated as biomarker for 
muscle wasting.
• Modulation of autophagy, N-terminal agrin fragments, modulation of 
Dok-7 expression, and sympathicomimetics are being investigated for 
their therapeutic function in neuromuscular junction-related muscle 
wasting.
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Figure 1. Major pathways involved in maintenance of neuromuscular junction and their links to 
clinical practice
Modulation of autophagy, of the agrin-Lrp4-MuSK signaling axis and of sympathetic 
activity have shown good results for treating sarcopenia and other forms of muscle wasting 
in rodent models. Thus, the therapeutic efficacies of stimulating autophagy, applying agrin 
N-terminal fragments, modulating Dok-7 expression and the use of sympathicomimetics are 
being explored. C-terminal agrin fragment (CAF) is being evaluated as a biomarker for 
muscle wasting. The upper panel schematically depicts therapeutic options (italic font) and 
biomarkers (regular font) for muscle wasting and their putative targets as discussed in the 
text. The lower panel indicates putative targets of therapeutic interventions, without being 
comprehensive.
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